More About the Risk of Ibrutinib-associated Bleeding

Clin Lymphoma Myeloma Leuk. 2017 May;17(5):326-327. doi: 10.1016/j.clml.2016.12.005. Epub 2017 Jan 10.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adenine / analogs & derivatives
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • Hemorrhage / diagnosis
  • Hemorrhage / drug therapy
  • Hemorrhage / etiology*
  • Hemorrhage / prevention & control
  • Humans
  • Piperidines
  • Protein Kinase Inhibitors / adverse effects*
  • Protein Kinase Inhibitors / therapeutic use
  • Pyrazoles / adverse effects*
  • Pyrazoles / therapeutic use
  • Pyrimidines / adverse effects*
  • Pyrimidines / therapeutic use
  • Severity of Illness Index

Substances

  • Antineoplastic Agents
  • Piperidines
  • Protein Kinase Inhibitors
  • Pyrazoles
  • Pyrimidines
  • ibrutinib
  • Adenine